FOOTPRINT-CAFÉS
Footprint Cafés, a new chain of sustainable enterprise cafés that will re-invest 100% of net profits into local communities has launched today. The brainchild of Georgina Hemmingway, a graduate of the Judge Business School at the University of Cambridge, Footprint Cafés has also attracted the personal endorsement and financial support of Horizon Discovery Group plc CEO, angel investor and enterprise champion, Dr. Darrin M. Disley who was honoured in the Queen’s Birthday Honours today with a Queen’s Award for Enterprise Promotion.
Footprint Cafés aims to establish itself in every corner of the world, becoming the brand for ethically-motivated tourists, giving them an authentic local experience combined with world class standards. Over the past two year Georgina has already proved the business model works with the success of New Leaf Book café in Siem Reap, Cambodia and is now expanding the concept to the cultural city of Battambang, Cambodia. Darrin Disley, who has become a trustee of the charity, has pledged an initial $150,000 cornerstone donation to a fundraising campaign that aims to raise $1 million by 2017.
Dr. Darrin M. Disley, winner of the Queen’s Award for Enterprise Promotion, commented, “I am delighted to be supporting such a uniquely pure and socially impactful project. Georgina’s idea for Footprint Cafés originated at the Judge Business School and it is fantastic to have been part of her journey and see this come to fruition today.
“Ethical entrepreneurship is at the heart of everything I do and is also a quality which is essential for the development of any successful and sustainable growth business. I am grateful not only to be receiving recognition for the work that I have done, but also to be able support Footprint Cafés mission of addressing global illiteracy, gender inequality and local community development, one fantastic Enterprise Café at a time.”
Footprint Cafés has also launched today a second hand book donation drive. Footprint Cafés will send your donated books to Cambodia, donating any children’s books to rural schools and selling all fiction books in their cafes as holiday reads for tourists. All money raised from book sales in the cafes will be given to the local community as grants for educational projects.
Georgina Hemmingway, Founder of Footprint Cafés, added: “Tourism is one of the fastest growing sectors in the world, and it also represents a significant opportunity to connect and empower local communities. At the moment that opportunity is often wasted with profits being drained off-shore to wealthy owners. Footprint Cafes will connect the global to the local by harnessing the spending power of tourism as a force for local change and empowerment one amazing café at a time.”
-Ends-
About the book drive
Footprint Cafes needs previously loved fiction and children’s books. Individuals are encouraged to write messages inside the books to the unknown Footprint customer. Individuals who would like to donate to the drive are asked to write to Footprint cafes directly to organise collection.
Contact info@footprintcafes.org for details on how to donate your books.
About Footprint Cafés – www.footprintcafes.org
Footprint Cafés is a triple-lock social enterprise that is undertaking an audacious but achievable mission of building a chain of sustainable Enterprise Cafés that break down barriers to education and deliver impacting change to local communities.
Founded by Georgina Hemmingway the enterprise builds on the success of over the past three years New Leaf Book café in Siem Reap, Cambodia which now employs 17 staff and has generated and donated its profits to eight local organisations tackling illiteracy, gender inequality and community development
The expansion of the model into the cultural city of Battambang, Cambodia supported by the first phase of a $1 million fund-raising drive has already begun with further plans to expand through Indochina and beyond,
About Dr. Darrin M. Disley’s Queens Award
Dr. Darrin M. Disley is the co-founder and Chief Executive Officer of Horizon Discovery Group plc, a successful UK listed life science company based in Cambridge. Dr Disley has made a major contribution to raising the profile of life sciences both in Cambridge and beyond.
As part of his endeavours, he has concentrated on a voluntary programme to raise the profile of entrepreneurship and its connection with life sciences. He has given many hours of time to aid young entrepreneurs through mentoring and speaking engagements. In the past four years, over 100 young entrepreneurs have benefited from his advice, time and financial support and almost a dozen businesses have been launched, raising over ten million pounds in capital. He remains an advisor to many of them.
Darrin also provides assistance to several social enterprises, students from underprivileged backgrounds and advises and assists two universities along with Cambridge University Entrepreneurs.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160420006628/en/
Contact:
For Media Enquiries
Consilium Strategic Communications
Amber
Fennell, Jessica Hodgson, Matthew Neal
Fennell@consilium-comms.com
Tel:
+44 (0) 203 709 5700
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom